G Protein-coupled Receptor Kinase 5 (GRK5) Inhibitors for Treatment of Heart Disease and Cancer

Back to all technologies
Download as PDF
Purdue University researchers have developed a series of compounds for the treatment of cardiovascular disease and cancer. These compounds target GRK5, a G protein-coupled receptor linked to progressive heart failure, hypertrophic cardiomyopathy, and cancer. Currently, there are no FDA-approved GRK5 inhibitors for treatment of these diseases. The Purdue compounds and their derivatives were specifically designed to target GRK5, they are highly potent selective and reversibly inhibit GRK5 with a half maximal inhibitory concentration in the nanomolar range. This current class of compounds has high therapeutic potential in the treatment of heart disease and cancer.

-Highly potent and selective GRK5 inhibitors
-Reversible mechanism of action
-Compounds and their derivatives have favorable drug properties

-Cardiovascular disease treatment
-Cancer treatment
-Drug discovery
Mar 1, 2023
PCT-Gov. Funding

Mar 1, 2022
Provisional-Gov. Funding
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org